Alkermes Advisory Committee Hears More About Refuse-To-File Letter Thanks To Industry Rep
Executive SummaryUS FDA’s decision to issue refuse-to-file action for Alkermes’ buprenorphine/samidorphan combo for major depressive disorder was one of the review issues brought to light by an unusually active advisory committee industry representative.
You may also be interested in...
US FDA accepts Alkermes' NDA for depression drug after issuing refuse-to-file letter just two weeks ago; unusual move falls outside agency's guidance on RTFs because no changes were made to submission and it wasn't filed over protest.
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.